Abstract
While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a large cohort of including 40 men and 60 women, we studied the long-term impact of prolactinoma treatment on bone mineral density (BMD) in men versus women, assessed adverse effects of a primary surgical or medical approach, and evaluated data for risk factors for impaired BMD at last follow-up using multivariate regression analyses. Median duration of follow-up was 79 months (range 13–408 months). Our data indicate that the prevalence of impaired BMD remained significantly higher in men (37%) than in women (7%, p < 0.001), despite the fact that hyperprolactinemia and hypogonadism are under control in the majority of men. We found that persistent hyperprolactinemia and male sex were independent risk factors for long-term bone impairment. Currently, osteoporosis prevention and treatment focus primarily on women, yet special attention to bone loss in men with prolactinomas is advised. Bone impairment as “end organ” reflects the full range of the disease and could become a surrogate marker for the severity of long-lasting hyperprolactinemia and associated hypogonadism.
Highlights
While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term
While some data indicate that hyperprolactinemic subjects do not demonstrate increased fractures despite their low bone density[16], other studies have reported a higher prevalence of vertebral fractures in particular in postmenopausal women with untreated prolactinomas, compared to patients treated with dopamine agonists (DAs)[15]
Between 1997 and 2015, osteodensitometric data were assessed in one hundred prolactinoma patients (40 men, 60 women) at Bern University Hospital at study entry and at longterm follow-up (> 12 months)
Summary
While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a large cohort of including 40 men and 60 women, we studied the long-term impact of prolactinoma treatment on bone mineral density (BMD) in men versus women, assessed adverse effects of a primary surgical or medical approach, and evaluated data for risk factors for impaired BMD at last follow-up using multivariate regression analyses. In a large cohort study in a dedicated tertiary referral center, we investigated whether prolactinoma treatment has an impact on the prevalence of bone impairment in both sexes over the long-term, and we assessed risk factors for impaired BMD that might guide better-targeted therapies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have